Compare WLDS & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WLDS | XBIO |
|---|---|---|
| Founded | 2014 | N/A |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7M | 6.9M |
| IPO Year | 2021 | 2011 |
| Metric | WLDS | XBIO |
|---|---|---|
| Price | $1.70 | $4.10 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 211.8K | 31.1K |
| Earning Date | 03-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.52 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,976,411.00 |
| Revenue This Year | N/A | $2.81 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 19.04 |
| 52 Week Low | $0.63 | $1.90 |
| 52 Week High | $11.40 | $13.93 |
| Indicator | WLDS | XBIO |
|---|---|---|
| Relative Strength Index (RSI) | 39.41 | 62.03 |
| Support Level | $1.21 | $2.82 |
| Resistance Level | $2.02 | N/A |
| Average True Range (ATR) | 0.29 | 0.35 |
| MACD | -0.09 | 0.01 |
| Stochastic Oscillator | 24.00 | 54.53 |
Wearable Devices Ltd develops and sells human-machine interface solutions for the smart wearables industry. These digital devices include consumer electronics, smart watches, smartphones, AR glasses, VR headsets, televisions, PCs, laptop computers, drones, robots, etc. The company has completed the transition phase from research and development to commercialization of technology into B2B and B2C products. Its products include Mudra Inspire, a band for the Apple Watch that allows touchless operation and control of Apple ecosystem devices such as iPhone, Mac computer, Apple TV, and iPad, inter alia.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.